Oral GLP-1 Candidate Aleniglipron Posts Weight Loss Data Rivaling Wegovy Pill in Phase II Trial
Structure Therapeutics recently shared new results from its latest obesity study. The data shows that their oral drug, aleniglipron,…
-
-
Wegovy Pill Triggers Oral Obesity Drug Race as Eli Lilly Advances Orforglipron Toward Approval
The new oral version of semaglutide has reached high prescription numbers since its recent release. A data firm called…
-
FDA Approves Oral Semaglutide for Weight Loss, Cheaper Alternative to Injectable GLP-1 Drugs
In January 2026, the U.S. Food and Drug Administration approved an oral formulation of semaglutide for weight management. This…
-
After CagriSema Blow, Novo Reveals Data for Obesity ‘Triple’
The world of weight loss medicine reached a major turning point in February 2026. Novo Nordisk shared two big…
-
Do GLP-1 Pills Cause Hair Loss?
Starting a GLP-1 journey is a massive step toward taking back control of your health and feeling like yourself…
-
Eli Lilly Diversifies Portfolio and Manufacturing Beyond Obesity
Stepping into a new phase of corporate growth requires a very clear and bold vision. Eli Lilly recently committed…
-
GLP-1 Pills for BMI Over 30: Clinical Eligibility and Treatment Considerations
Taking the first step toward managing your weight is a huge milestone for your long-term health. For many, this…
-
Obesity and GLP-1 Pills: Clinical Differences Explained
The landscape of metabolic health is undergoing its most significant transformation since the discovery of insulin. For the past…
